Home » Therapeutic Monoclonal Antibodies Market

Therapeutic Monoclonal Antibodies Market Growth, Future Prospects & Competitive Analysis, 2016 – 2024

Price: $4999

Published: | Report ID: 11175 | Report Format : PDF


Following the approval of the first monoclonal antibody in 1986, approval and sales were flat until the introduction of the first chimeric monoclonal antibodies. With further approvals of humanized and fully human monoclonal antibodies, the market for therapeutic monoclonal antibodies experienced a significant surge to become a multi-billion dollar market in the current decade. With over 300 monoclonal antibody candidates under assessment, this segment will continue to drive the sales of biopharmaceutical products. The number of monoclonal antibody products being made commercially available is rising consistently, with an addition of 3–5 products every year.

Perpetually expanding interest in antibody product development is significantly driven by progress in our understanding of diseases. Areas such as proteomics and genomics continue to provide newer targets for disease modulation. Monoclonal antibodies are claimed to provide the fastest route of clinical proof of concept for the inhibition, blocking, or activation of new targets.

Since the production of monoclonal antibody products is easily open to several platform-based approaches and the antibodies are mostly well-tolerated and specific, the risk of safety issues in human clinical trials of monoclonal antibody products is rare. Hence, after successful proof-of-concept studies with these products, they are observed to undergo rapid commercialization, thereby gaining a first-to-market advantage. Another factor facilitating the growth of this market is the overall expansion of the global pharmaceuticals market, resulting from growth in the senescent population and the evolving standard of living in emerging economies.

The global platelet-rich plasma market is segmented on the following bases:

  • Asia Pacific
  •  Rest of Europe
  • Germany
  • UK
  • Europe
  • Canada
  • US
  • North America
  • Geography
  • Protein
  • mAb
  • Molecule Type
  • Others
  • Rebif
  • Avonex
  • Lucentis
  • Neulasta
  • Avastin
  • Herceptin
  • Remicade
  • Rituxan
  • Enbrel
  • Humira
  • Top Drugs
  • Japan
  • China
  •  Rest of APAC
  • Latin America

Middle East and Africa

Key players identified for the therapeutic monoclonal antibody market include but are not limited to:

Abbott Laboratories, AbbVie Inc., Amgen, Inc., AstraZeneca, Bayer AG, Biogen Inc., Bristol-Myers Squibb Co., Daiichi Sankyo Company, Ltd., Eli Lilly and Company, GlaxoSmithKline Plc., Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Merck & Co., Inc., Mylan, Novartis AG, Novo Nordisk A/S, Pf

This report offers the following:

  • An overview of the global markets for therapeutic monoclonal antibodies
  • Market trends assessment for the period 2013–2024, with historical information for 2013 and 2014 and projections through 2024, with respective CAGRs during 2016–2024
  • Qualitative assessment tools such as market drivers, challenges, future prospects, major commercial events, etc.
  • Market competition scrutiny tools such as market share assessment, an attractive investment proposition, and others
  • Focus on each level of market segmentation based on product approvals, launches, and current and anticipated market dynamics.
  • A general overview of the industry structure
  • Company profiles highlight key information about the major players operating in the therapeutic monoclonal antibodies market.

 Frequently Asked Questions:

What is the size of Therapeutic Monoclonal Antibodies Market?

The market for Therapeutic Monoclonal Antibodies Market is expected to reach XX Bn in 2024.

What is the Therapeutic Monoclonal Antibodies Market CAGR?

The Therapeutic Monoclonal Antibodies Market is expected to see significant CAGR growth over the coming years, at 5.6%.

What is the Forecast period considered for Therapeutic Monoclonal Antibodies Market?

The report is forecasted from 2016-2024.

What is the base year considered for Therapeutic Monoclonal Antibodies Market?

The base year of this report is 2015.

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market

Report ID: 33712

Tracheitis Treatment Market

Report ID: 33694

Neuralgia Treatment Market

Report ID: 33681

Clostridioides Difficile (C. diff) Treatment Market

Report ID: 33667

Sphingosine-1-Receptor Modulators Drugs Market

Report ID: 33649

Neuromyelitis Optica Therapy Market

Report ID: 33583

Pediatric Bladder Treatment Market

Report ID: 33540

Neurotrophic Keratitis Treatment Market

Report ID: 33425

Precision Medicine Market

Report ID: 11123

Eosinophilic Pneumonia Treatment Market

Report ID: 5486

Myelodysplastic Syndrome Market

Report ID: 32821

US Retail Pharmacy Market

Report ID: 32801

Purchase Options

Delivery Format: Excel.
Designed for the individual purchaser.
Users located at a single corporate site or regional office.
Allowed for unlimited sharing globally within one company.
Smallform of Sample request

Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –


+91 6232 49 3207


24/7 Research Support


– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN